JP2022546711A5 - - Google Patents
Info
- Publication number
- JP2022546711A5 JP2022546711A5 JP2022514215A JP2022514215A JP2022546711A5 JP 2022546711 A5 JP2022546711 A5 JP 2022546711A5 JP 2022514215 A JP2022514215 A JP 2022514215A JP 2022514215 A JP2022514215 A JP 2022514215A JP 2022546711 A5 JP2022546711 A5 JP 2022546711A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- formula
- independently
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895476P | 2019-09-03 | 2019-09-03 | |
| US62/895,476 | 2019-09-03 | ||
| PCT/US2020/049248 WO2021046250A1 (en) | 2019-09-03 | 2020-09-03 | Methods of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546711A JP2022546711A (ja) | 2022-11-07 |
| JP2022546711A5 true JP2022546711A5 (cg-RX-API-DMAC10.html) | 2023-08-21 |
| JP7631319B2 JP7631319B2 (ja) | 2025-02-18 |
Family
ID=74853030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514215A Active JP7631319B2 (ja) | 2019-09-03 | 2020-09-03 | 治療方法 |
Country Status (11)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7493460B2 (ja) | 2018-05-25 | 2024-05-31 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2020146384A1 (en) | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12599603B2 (en) | 2019-09-03 | 2026-04-14 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| MX2024010993A (es) * | 2022-03-11 | 2024-09-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690935A (en) | 1983-03-31 | 1987-09-01 | Wayne State University | Inhibition of tumor growth and metastasis with calcium channel blocker compounds |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2939676A1 (en) | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2009322903A1 (en) * | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EA201170769A1 (ru) | 2008-12-06 | 2012-02-28 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| WO2012177263A1 (en) | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| JP6224597B2 (ja) | 2011-09-27 | 2017-11-01 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | グリオーマを処置するための組成物及び方法 |
| WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| US9499562B2 (en) | 2012-06-18 | 2016-11-22 | Dart Neuroscience (Cayman) Ltd. | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds |
| DK2970279T3 (da) | 2013-03-15 | 2020-11-30 | Intra Cellular Therapies Inc | Organiske forbindelser |
| ES2717688T3 (es) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| DK3157926T3 (da) * | 2014-06-20 | 2019-08-19 | Intra Cellular Therapies Inc | Organiske forbindelser |
| US10131671B2 (en) * | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2961212C (en) * | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| US10849862B2 (en) * | 2014-12-26 | 2020-12-01 | Theravalues Corporation | Formulation of curcumin and anti-PD-1 antibody |
| EP3288980B1 (en) | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| US10912748B2 (en) * | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| US11291666B2 (en) | 2016-09-12 | 2022-04-05 | Intra-Cellular Therapies, Inc. | Uses |
| MA46716A (fr) | 2016-11-03 | 2019-09-11 | Juno Therapeutics Inc | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie |
| CA3047579A1 (en) | 2016-12-22 | 2018-06-28 | Abbvie Inc. | Compositions and methods of enhancing or augmenting type i ifn production |
| EP3612839A1 (en) | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy |
| AU2018325445A1 (en) | 2017-08-31 | 2020-03-19 | Abbvie Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof |
| EP3856191A4 (en) | 2018-09-25 | 2022-06-22 | Intra-Cellular Therapies, Inc. | NOVEL USES |
| WO2020146384A1 (en) * | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12599603B2 (en) | 2019-09-03 | 2026-04-14 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| MX2024010993A (es) | 2022-03-11 | 2024-09-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
-
2020
- 2020-09-03 US US17/640,050 patent/US12599603B2/en active Active
- 2020-09-03 AU AU2020343329A patent/AU2020343329C1/en active Active
- 2020-09-03 WO PCT/US2020/049248 patent/WO2021046250A1/en not_active Ceased
- 2020-09-03 CA CA3147071A patent/CA3147071A1/en active Pending
- 2020-09-03 JP JP2022514215A patent/JP7631319B2/ja active Active
- 2020-09-03 EP EP20860677.2A patent/EP4025218A4/en active Pending
- 2020-09-03 BR BR112022003670A patent/BR112022003670A2/pt unknown
- 2020-09-03 MX MX2022002607A patent/MX2022002607A/es unknown
- 2020-09-03 KR KR1020227010604A patent/KR20220054853A/ko active Pending
- 2020-09-03 CN CN202080062144.3A patent/CN114340636A/zh active Pending
-
2022
- 2022-02-28 IL IL290983A patent/IL290983A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP2020533277A5 (cg-RX-API-DMAC10.html) | ||
| JP2025163128A5 (cg-RX-API-DMAC10.html) | ||
| RU2602498C2 (ru) | Соединения и композиции для стабилизации индуцируемого гипоксией фактора-2 альфа как способ лечения рака | |
| JP2022185107A5 (cg-RX-API-DMAC10.html) | ||
| JP2020521740A5 (cg-RX-API-DMAC10.html) | ||
| JP2017528498A5 (cg-RX-API-DMAC10.html) | ||
| RU2008143237A (ru) | Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам | |
| JP2022520448A5 (cg-RX-API-DMAC10.html) | ||
| RU2002117422A (ru) | 4-пиримидинил-N-ацил-L-фенилаланины | |
| RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
| RU2002120515A (ru) | Гетероциклические соединения, содержащие сульфонамидные группы | |
| RU2001121987A (ru) | Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов | |
| JP2004538322A (ja) | 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性 | |
| RU2004122414A (ru) | Цис-2,4,5-трифенилимидазолины и их применение для лечения опухолевых заболеваний | |
| JP2023509359A5 (cg-RX-API-DMAC10.html) | ||
| CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
| JP2025509446A5 (cg-RX-API-DMAC10.html) | ||
| JP2025508323A5 (cg-RX-API-DMAC10.html) | ||
| RU2003127731A (ru) | Ингибиторы металлопротеиназ | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2022522942A5 (cg-RX-API-DMAC10.html) | ||
| KR920006322A (ko) | 벤젠, 피리딘 및 피리미딘 유도체 | |
| CA2461916A1 (en) | Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis | |
| JP2023538159A5 (cg-RX-API-DMAC10.html) |